Ocugen Eyes Broad Retinitis Pigmentosa Indication With One Gene Therapy
Executive Summary
Emerging Company Profile: Turning to gene therapy after its dry eye drug didn’t work out, Ocugen hopes to overcome financial challenges to bring a gene therapy into the clinic for numerous mutations of RP.
You may also be interested in...
Deal Watch: Gilead To Use Insitro’s AI/Functional Genomics Tech For NASH Targets
Start-up Insitro will attempt to optimize up to five NASH targets for Gilead under three-year alliance. Catalent buys gene therapy CDMO Paragon for $1.2bn, Boehringer partners with PureTech in GI cancer, while Fibrocell inks gene therapy pact with Castle Creek.
Ocugen Heads Toward Phase III In Dry Eye With Potential Benefits Over Older Drugs
Biotech hopes to counter established Restasis and Xiidra in dry eye with a combination of two approved ophthalmology eye drops, offering quicker onset of action, tolerability and strong efficacy.
AbbVie To Switch Track In Alzheimer’s From Tau To Beta-Amyloid
Citing the FDA approval of Biogen’s Aduhelm, AbbVie tells quarterly call it will end development of anti-tau Alzheimer’s candidate and seek to develop a quick-acting beta-amyloid therapy.